United Therapeutics (UTHR) Scheduled to Post Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) will be issuing its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $5.63 per share for the quarter.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same quarter in the previous year, the firm posted $2.67 earnings per share. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. On average, analysts expect United Therapeutics to post $23 EPS for the current fiscal year and $25 EPS for the next fiscal year.

United Therapeutics Stock Performance

Shares of UTHR stock traded down $2.06 during trading hours on Thursday, hitting $234.94. 81,041 shares of the company were exchanged, compared to its average volume of 435,203. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $11.06 billion, a price-to-earnings ratio of 11.86 and a beta of 0.52. United Therapeutics has a 52-week low of $204.44 and a 52-week high of $261.54. The firm has a fifty day simple moving average of $232.93 and a 200 day simple moving average of $228.74.

Analyst Ratings Changes

Several research firms recently issued reports on UTHR. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $213.00 to $215.00 in a research note on Monday, February 12th. Wedbush restated an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $294.25.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the completion of the sale, the executive vice president now owns 36,599 shares of the company’s stock, valued at approximately $7,869,150.99. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,756.70. The disclosure for this sale can be found here. Insiders have sold 133,390 shares of company stock valued at $31,379,925 over the last ninety days. Insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.